English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Pharma & Biotech BioTech (Sci&Research)
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020
Jun 09, 2020 20:00 HKT
Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits
Jun 09, 2020 11:00 HKT
Blockchain Holdings Ltd. subsidiary TraceSafe and Toronto Wolfpack Sign Contract for Wearable Technology to Safely Reopen Lamport Stadium
Jun 02, 2020 00:00 HKT
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
Jun 01, 2020 13:00 HKT
After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test
May 30, 2020 10:00 HKT
Sino Biopharmaceutical Announces 2020 First Quarterly Results
May 28, 2020 19:59 HKT
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences' COVID-19 Neutralizing Antibodies
May 27, 2020 10:41 HKT
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration
May 26, 2020 17:16 HKT
Novotech and Endpoints to present APAC Clinical Trial webinar series
May 26, 2020 19:00 HKT
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
May 20, 2020 18:15 HKT
Agilex Biolabs Presents the Australian Advantage, including the World's Largest Rebate on Clinical Trial Spend, at BIO Korea 2020
May 20, 2020 16:00 HKT
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting
May 19, 2020 17:50 HKT
Cyber Company to Supply 50M Health "COVI-PASS(TM)"
May 08, 2020 14:30 HKT
Novotech COVID-19 Clinical Trial Clients Benefit from New Asia-Pacific Fast-Track Review Processes
Apr 28, 2020 19:00 HKT
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)
Apr 27, 2020 09:50 HKT
Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
Apr 24, 2020 16:22 HKT
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Apr 24, 2020 10:00 HKT
Blockchain Holdings Enters into Definitive Agreement for Acquisition of COVID-19 Quarantine Management Product TRACEsafe
Apr 23, 2020 21:00 HKT
CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration
Apr 23, 2020 13:45 HKT
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial
Apr 22, 2020 11:08 HKT
<< Previous  Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: